IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer

被引:20
|
作者
Westeel, V.
Lebitasy, M. P.
Mercier, M.
Girard, P.
Barlesi, F.
Blanchon, F.
Tredaniel, J.
Bonnette, P.
Woronoff-Lemsi, M. C.
Breton, J. L.
Azarian, R.
Falcoz, P. E.
Friard, S.
Geriniere, L.
Laporte, S.
Lemarie, E.
Quoix, E.
Zalcman, G.
Guigay, J.
Morin, F.
Milleron, B.
Depierre, A.
机构
[1] Univ Franche Comte, CHU Besancon, Serv Pneumol, F-25030 Besancon, France
[2] IFCT, Paris, France
[3] Univ Franche Comte, Serv Biomath, F-25030 Besancon, France
[4] Ctr Mutualiste Montsouris, Paris, France
[5] APHM, Marseille, France
[6] APHP Hop St Louis, Paris, France
[7] Ctr Hosp Foch, Suresnes, France
[8] CH Versailles, Versailles, France
[9] Hop Foch, Suresnes, France
[10] Ctr Hosp Lyon Sud, HCL, F-69310 Pierre Benite, France
[11] CHU Tours, Tours, France
[12] CHU Strasbourg, F-67000 Strasbourg, France
[13] CHU Caen, F-14000 Caen, France
[14] Inst Gustave Roussy, Villejuif, France
[15] APHP Hop Tenon, Paris, France
关键词
lung cancer; post-operative follow-up; randomised trial; surgery; non-small cell lung cancer;
D O I
10.1016/S0761-8425(07)91135-3
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background The authorities advocate a minimalist attitude towards the follow-up of resected bronchial carcinoma (clinical examination and chest x-ray). A survey showed that 70% of French respiratory physicians have chosen to use the CT scanner and often endoscopy. The published data are equivocal and are often based on retrospective studies. Lung cancer is a good model for a study of post-operative surveillance. Recurrences often occur in easily observed areas, they may be detected while still asymptomatic and are sometimes potentially curable. Second primary tumours may develop at the same site. Methods The Intergroupe Francophone de Cancerologie Thoracique (IFCT) has initiated a trial comparing simple follow-up (clinical examination, chest x-ray) with a more intensive followup (CT scan, fibreoptic bronchoscopy). The surveillance will take place every 6 months for 2 years and then annually until 5 years. Expected results The main aim is to determine whether intensive follow-up improves patient survival. The opposite question is equally important. If an expensive and demanding follow-up does not affect the chances of cure these results will influence our practice.
引用
收藏
页码:645 / 652
页数:8
相关论文
共 50 条
  • [31] A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer
    Yamashita, Yoshinori
    Kataoka, Kazuhiko
    Ishida, Teruyoshi
    Matsuura, Motoki
    Seno, Noritomo
    Mukaida, Hidenori
    Miyahara, Eiji
    Miyata, Yoshihiro
    Okita, Riki
    Shimizu, Katsuhiko
    Watari, Masanobu
    Okumichi, Tsuneo
    Okada, Morihito
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : 612 - 616
  • [32] Feasibility Study of Adjuvant Chemotherapy of S-1 and Carboplatin for Completely Resected Non-Small Cell Lung Cancer
    Komazaki, Yoshitoshi
    Sakashita, Hiroyuki
    Furuiye, Masashi
    Fujie, Toshihide
    Tamaoka, Meiyo
    Sumi, Yuki
    Miyazaki, Yasunari
    Kojima, Katsuo
    Jin, Yasuto
    Inase, Naohiko
    CHEMOTHERAPY, 2013, 59 (01) : 35 - 41
  • [33] Prognosis associated with synchronous or metachronous multiple primary malignancies in patients with completely resected non-small cell lung cancer
    Komatsu, Hiroaki
    Izumi, Nobuhiro
    Tsukioka, Takuma
    Inoue, Hidetoshi
    Hara, Kantaro
    Miyamoto, Hikaru
    Nishiyama, Noritoshi
    SURGERY TODAY, 2019, 49 (04) : 343 - 349
  • [34] Prognosis associated with synchronous or metachronous multiple primary malignancies in patients with completely resected non-small cell lung cancer
    Hiroaki Komatsu
    Nobuhiro Izumi
    Takuma Tsukioka
    Hidetoshi Inoue
    Kantaro Hara
    Hikaru Miyamoto
    Noritoshi Nishiyama
    Surgery Today, 2019, 49 : 343 - 349
  • [35] FEASIBILITY STUDY OF S-1 ADJUVANT CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
    Okumura, Shunsuke
    Sasaki, Takaaki
    Minami, Yoshinori
    Kitada, Masahiro
    Ohsaki, Yoshinobu
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1327 - S1328
  • [36] A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304)
    Tada, H
    Tsuchiya, R
    Ichinose, Y
    Koike, T
    Nishizawa, N
    Nagai, K
    Kato, H
    LUNG CANCER, 2004, 43 (02) : 167 - 173
  • [37] Comparing Two Common Radiotherapy Regimens in Non-Small Cell Lung Cancer - A Retrospective Study
    Poon, W.
    Mcloone, P.
    Flanagan, Y.
    Currie, S.
    Keiller, D.
    Harrow, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S839 - S840
  • [38] A phase III randomized trial of postoperative adjuvant therapy in Stage II or IIIA completely resected non-small cell lung cancer
    Yoon, S
    Choi, E
    Kim, S
    Suh, C
    Lee, J
    Shim, T
    Kim, W
    Kim, D
    Park, S
    Park, C
    LUNG CANCER, 2005, 49 : S288 - S288
  • [39] Supraclavicular Recurrence in Completely Resected (y)pN2 Non-Small Cell Lung Cancer: Implications for Postoperative Radiotherapy
    Liu, Liang
    Zheng, Zhiqin
    Li, Juan
    Li, Yuan
    Ni, Jianjiao
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [40] A Phase III Study of Adjuvant Chemotherapy in Patients with Completely Resected, Node-Negative Non-Small Cell Lung Cancer
    Kunitoh, H.
    Sakurai, H.
    Tsuboi, M.
    Wakabayashi, M.
    Okada, M.
    Suzuki, K.
    Ikeda, N.
    Takahama, M.
    Takenoyama, M.
    Ohde, Y.
    Yoshiya, K.
    Matsumoto, I.
    Yamashita, M.
    Marutsuka, T.
    Date, H.
    Hasumi, T.
    Yamashita, Y.
    Okumura, N.
    Watanabe, S.
    Asamura, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S270 - S271